JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.
What’s New and What’s Worth Reviewing: PAUL JENSEN
TEST FOR 55th ANNUAL POST GRADUATE SEMINAR
What’s New and What’s Worth Reviewing: Paul Jensen
You will need a minimum of 4 / 5 questions answered correctly to pass this test and be issued CE credit.
Sign in to Google
to save your progress.
Learn more
* Indicates required question
ARBO / OE TRACKER #
*
Your answer
1.
Regarding Oxervate
*
a. Is a neurotrophin
b. Does not affect the cornea
c. Is not FDA approved for any use yet
d. Is inexpensive
2.
Regarding Visomitin
*
a. Has never been used on humans
b. Has only been found to be useful for dry eyes
c. Is a powerful antioxidant
d. Does not help repair damaged tissue
3.
Regarding Acthar
*
a. Has the exact same side effects as other steroids
b. Is only injectable
c. Has no use in eye care
d. Never has systemic side effects
4.
Corneal staining in the superior limbus
*
a. Is suspicious of lid wiper epitheliopathy
b. Never happens
c. Never requires treatment
d. Looks the same as other staining
5.
Punctal plugs
*
a. Are a strong consideration for patients with low tear meniscus
b. Should be tested with an organized trial
c. Can help postnasal drip
d. May give immediate relief of symptoms
e. All of the above
Submit
Clear form
Never submit passwords through Google Forms.
This form was created inside of Optometric Physicians of Washington.
Does this form look suspicious?
Report
Forms
